Estimation of Radiation Dose from Patients Undergoing <sup>99m</sup>Tc-Methoxy Isobutyl Isonitrile Myocardial Perfusion Imaging to the General Public and Nuclear Medicine Technicians_West China Medical Journal

Authors：

 JiangLisha , ZengYu , YangXiaochuan ,  LiuBin

Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

LiuBin, Email: binl@foxmail.com

Keywords：

^99mTc-methoxy isobutyl isonitrile; Myocardial perfusion imaging; General public; Radiation dose; Radiation protection

DOI：

10.7507/1002-0179.201600338

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To estimate the radiation dose (RD) to the general public and nuclear medicine technicians from patients undergoing ^99mTc-methoxy isobutyl isonitrile (MIBI) myocardial perfusion imaging. Methods From January to June 2015, 55 patients including 30 males and 25 females aged between 25 and 87 years[averaging (63.6±15.1)years] ready to undergo myocardial perfusion scintigraphy with ^99mTc-MIBI were prospectively recruited in this study. Approximately at hour 1.5 after injection of ^99mTc-MIBI, whole-body dose-equivalent rate was measured with a radiation-survey meter at 0.3 meter and 1.0 meter from the patients. On the basis of human ^99mTc-MIBI metabolic rate proposed by the International Commission of Radiological Protection and human social contact model proposed by the National Council on Radiation Protection and Measurements, the RDs to the general public from patients who had completed ^99mTc-MIBI myocardial perfusion imaging and left nuclear medicine department were calculated. On the assumption that a nuclear medicine technician typically spent 5 minutes at a distance of 0.3 meter for positioning the patient, the technician's RD was also estimated. Results The RD to a family member sleeping with the patient at night was predicted to be 42.88-160.55 μSv, to a family member contacting the patient at daytime 7.50-29.38 μSv, to a colleague 9.89-38.78 μSv and to a nearby passenger 124.48-466.06 μSv. The RD to a technician per ^99mTc-MIBI myocardial perfusion imaging procedure was predicted to be 1.72-6.44 μSv. Conclusion The predicted RDs to the general public and technicians from exposure of patients undergoing ^99mTc-MIBI myocardial perfusion imaging are significantly lower than the regulatory dose limits.

Citation： JiangLisha, ZengYu, YangXiaochuan, LiuBin. Estimation of Radiation Dose from Patients Undergoing ^99mTc-Methoxy Isobutyl Isonitrile Myocardial Perfusion Imaging to the General Public and Nuclear Medicine Technicians. West China Medical Journal, 2016, 31(7): 1243-1246. doi: 10.7507/1002-0179.201600338 Copy

1.	Bolus NE. NCRP report 160 and what it means for medical imaging and nuclear medicine[J]. J Nucl Med Technol, 2013, 41(4):255-260.
2.	Kamiya K, Ozasa K, Akiba S, et al. Long-term effects of radiation exposure on health[J]. Lancet, 2015, 386(9992):469-478.
3.	Botnar RM, Ebersberger H, Noerenberg D, et al. Molecular imaging in cardiovascular diseases[J]. Rofo, 2015, 187(2):92-101.
4.	刘斌, 曾宇, 黄蕤, 等. 心肌灌注显像CT衰减校正伪影产生的初步研究[J]. 华西医学, 2009, 24(2):388-391.
5.	Verberne HJ, Acampa W, Anagnostopoulos C, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT:2015 revision[J]. Eur J Nucl Med Mol Imaging, 2015, 42(12):1929-1940.
6.	Travin MI. Pitfalls and limitations of radionuclide and hybrid cardiac imaging[J]. Semin Nucl Med, 2015, 45(5):392-410.
7.	Olmstead C, Cruz K, Stodilka R, et al. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol[J]. Nucl Med Commun, 2015, 36(2):129-134.
8.	NCRP. Management of radionuclide therapy patients. NCRP Report No. 155. National Council on Radiation Protection and Measurements, 2006.
9.	Liu B, Peng W, Huang R, et al. Thyroid cancer:radiation safety precautions in ¹³¹I therapy based on actual biokinetic measurements[J]. Radiology, 2014, 273(1):211-219.
10.	Liu B, Tian R, Peng W, et al. Radiation safety precautions in (131)I therapy of Graves' disease based on actual biokinetic measurements[J]. J Clin Endocrinol Metab, 2015, 100(8):2934-2941.
11.	Mattsson S. Patient dosimetry in nuclear medicine[J]. Radiat Prot Dosimetry, 2015, 165(1/2/3/4):416-423.
12.	Chen MY. Radiation protection and regulations for the nuclear medicine physician[J]. Semin Nucl Med, 2014, 44(3):215-228.
13.	Soliman K, Alenezi A. Estimation of patient attenuation factor for iodine-131 based on direct dose rate measurements from radioiodine therapy patients[J]. Nucl Med Commun, 2015, 36(2):125-128.
14.	Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2015, 25(7):716-759.
15.	Cool DA, Lazo E, Tattersall P, et al. ICRP publication 125:radiological protection in security screening[J]. Ann ICRP, 2014, 43(2):5-40.
16.	Melo DR, Brill AB, Zanzonico P, et al. Organ dose estimates for hyperthyroid patients treated with (131)I:an update of the thyrotoxicosis follow-up study[J]. Radiat Res, 2015, 184(6):595-610.
17.	Vogiatzi S, Liossis A, Lamprinakou M. Thyroid cancer radioiodine therapy:health service performance and radiation safety[J]. Radiat Prot Dosimetry, 2015, 165(1/2/3/4):434-438.
18.	Soliman K, Alenezi A, Bakkari M, et al. Measurement and analysis of patient attenuation correction factor during radioiodine therapy[J]. Radiat Prot Dosimetry, 2015, 165(1/2/3/4):448-451.

1. Bolus NE. NCRP report 160 and what it means for medical imaging and nuclear medicine[J]. J Nucl Med Technol, 2013, 41(4):255-260.
2. Kamiya K, Ozasa K, Akiba S, et al. Long-term effects of radiation exposure on health[J]. Lancet, 2015, 386(9992):469-478.
3. Botnar RM, Ebersberger H, Noerenberg D, et al. Molecular imaging in cardiovascular diseases[J]. Rofo, 2015, 187(2):92-101.
4. 刘斌, 曾宇, 黄蕤, 等. 心肌灌注显像CT衰减校正伪影产生的初步研究[J]. 华西医学, 2009, 24(2):388-391.
5. Verberne HJ, Acampa W, Anagnostopoulos C, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT:2015 revision[J]. Eur J Nucl Med Mol Imaging, 2015, 42(12):1929-1940.
6. Travin MI. Pitfalls and limitations of radionuclide and hybrid cardiac imaging[J]. Semin Nucl Med, 2015, 45(5):392-410.
7. Olmstead C, Cruz K, Stodilka R, et al. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol[J]. Nucl Med Commun, 2015, 36(2):129-134.
8. NCRP. Management of radionuclide therapy patients. NCRP Report No. 155. National Council on Radiation Protection and Measurements, 2006.
9. Liu B, Peng W, Huang R, et al. Thyroid cancer:radiation safety precautions in ¹³¹I therapy based on actual biokinetic measurements[J]. Radiology, 2014, 273(1):211-219.
10. Liu B, Tian R, Peng W, et al. Radiation safety precautions in (131)I therapy of Graves' disease based on actual biokinetic measurements[J]. J Clin Endocrinol Metab, 2015, 100(8):2934-2941.
11. Mattsson S. Patient dosimetry in nuclear medicine[J]. Radiat Prot Dosimetry, 2015, 165(1/2/3/4):416-423.
12. Chen MY. Radiation protection and regulations for the nuclear medicine physician[J]. Semin Nucl Med, 2014, 44(3):215-228.
13. Soliman K, Alenezi A. Estimation of patient attenuation factor for iodine-131 based on direct dose rate measurements from radioiodine therapy patients[J]. Nucl Med Commun, 2015, 36(2):125-128.
14. Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2015, 25(7):716-759.
15. Cool DA, Lazo E, Tattersall P, et al. ICRP publication 125:radiological protection in security screening[J]. Ann ICRP, 2014, 43(2):5-40.
16. Melo DR, Brill AB, Zanzonico P, et al. Organ dose estimates for hyperthyroid patients treated with (131)I:an update of the thyrotoxicosis follow-up study[J]. Radiat Res, 2015, 184(6):595-610.
17. Vogiatzi S, Liossis A, Lamprinakou M. Thyroid cancer radioiodine therapy:health service performance and radiation safety[J]. Radiat Prot Dosimetry, 2015, 165(1/2/3/4):434-438.
18. Soliman K, Alenezi A, Bakkari M, et al. Measurement and analysis of patient attenuation correction factor during radioiodine therapy[J]. Radiat Prot Dosimetry, 2015, 165(1/2/3/4):448-451.

West China Medical Journal

Estimation of Radiation Dose from Patients Undergoing ^99mTc-Methoxy Isobutyl Isonitrile Myocardial Perfusion Imaging to the General Public and Nuclear Medicine Technicians

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

West China Medical Journal

Estimation of Radiation Dose from Patients Undergoing 99mTc-Methoxy Isobutyl Isonitrile Myocardial Perfusion Imaging to the General Public and Nuclear Medicine Technicians

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

Estimation of Radiation Dose from Patients Undergoing ^99mTc-Methoxy Isobutyl Isonitrile Myocardial Perfusion Imaging to the General Public and Nuclear Medicine Technicians